Pharmaceutical Technology Europe
Why do the biotech ventures mange to have such promising drug candidates while pharmaceutical R&D is facing a drug deficit?
Sylvia M. Findlay
Advertisement
Sylvia Findlay is Pharmaceuticals and Biotechnology Industry Analyst at Frost & Sullivan.
Articles by Sylvia M. Findlay
Pharmaceutical Technology Europe
FDA has tightened up the approval of new drugs, ensuring careful scrutiny of clinical data and stringent scanning to analyse the probable side-effects of a new drug
Advertisement
Latest Updated Articles
- New age therapies
December 1st 2006
Spotlight: Market analysis Beating the blockbuster bluesJanuary 1st 2006
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA Duloxetine Recall Highlights Generic Manufacturing Quality Gaps
2
Germany Pharma Tariff Threat: What Manufacturers Need to Know
3
Why Pharma Dealmaking Slowed in Q1 2026 and What Is Coming Next
4
PharmTech Weekly Roundup—June 19, 2026
5